Loading…
Rallybio Corporation is projected to rise to $17.45 by 2027, a +20% move from its current price of $14.53. RLYB is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $14.03 | $14.53 | $15.05 | -0.02% |
| May 30 | $13.82 | $14.52 | $15.26 | -0.04% |
| May 31 | $13.66 | $14.52 | $15.43 | -0.06% |
| Jun 1 | $13.53 | $14.52 | $15.57 | -0.09% |
| Jun 2 | $13.42 | $14.51 | $15.70 | -0.11% |
| Jun 3 | $13.32 | $14.51 | $15.81 | -0.13% |
| Jun 4 | $13.22 | $14.51 | $15.92 | -0.15% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $13.22 | $14.51 | $15.92 | -0.15% |
| Week 2 | $12.70 | $14.49 | $16.52 | -0.30% |
| Week 3 | $12.32 | $14.46 | $16.99 | -0.45% |
| Week 4 | $12.00 | $14.44 | $17.39 | -0.60% |
| Week 5 | $11.72 | $14.42 | $17.74 | -0.75% |
| Week 6 | $11.47 | $14.40 | $18.07 | -0.91% |
| Week 7 | $11.25 | $14.38 | $18.38 | -1.06% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Rallybio Corporation is a clinical-stage biotechnology company focused on developing and commercializing therapies for severe and rare diseases. Its lead product candidate is RLYB116, an inhibitor of complement component 5 (C5) to treat diseases of complement dysregulation, which has completed a phase 1 trial. RLYB332 is a preclinical antibody for the treatment of severe anemia with ineffective erythropoiesis and iron overload.
Rallybio was founded in 2018 and is headquartered in New Haven, Connecticut. The company has a strategic alliance with AbCellera to discover, develop, and commercialize novel antibody-based therapeutics for rare diseases, as well as a collaboration with Johnson & Johnson to provide therapeutic solutions for pregnant individuals at risk of fetal and neonatal alloimmune thrombocytopenia.
Rallybio Corporation (RLYB) is currently priced at $14.53 and has a market cap of $76.98M, ranking 4340 by market cap. The current price sits within a 30-day range of $11.53 to $18.31, and the stock shows bullish technical sentiment with a long-run growth outlook implied by the annualized forecast. The average price targets by year suggest upside beyond the current price, with the 2026 average at $14.53 and substantial gains projected through 2050.
A major floor 70.2% below — a decisive break under it would weaken the trend.
The nearest floor, 43.4% below — buyers have tended to step in here.
The nearest ceiling, 9.3% above — a clean break opens room to run.
A major ceiling 41.3% above — clearing it would confirm fresh momentum.
Key RLYB support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of RLYB market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $15.01 | Sell | $14.81 | Sell |
| MA 10 | $14.62 | Sell | $14.52 | Buy |
| MA 20 | $13.68 | Buy | $13.52 | Buy |
| MA 50 | $10.59 | Buy | $11.32 | Buy |
| MA 100 | $8.50 | Buy | $9.41 | Buy |
| MA 200 | $6.73 | Buy | $7.83 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 65.58 | Neutral |
| Stoch RSI (14) | 0.00 | Buy |
| CCI (20) | 41.38 | Neutral |
| Williams %R (14) | -71.81 | Info |
| MACD (12,26,9) | -0.07 | Sell |
| ROC (12) | 1.04 | Buy |
| Bollinger %B (20,2) | 0.61 | Neutral |
| Stochastic %K (14) | 28.19 | Neutral |
| TRIX (15) | 1.99 | Buy |
| Awesome (5,34) | 3.50 | Buy |
| Ultimate (7,14,28) | 55.83 | Neutral |
| Momentum (10) | 0.50 | Buy |
| Aroon Osc (25) | 92.00 | Buy |
| Hull MA (9) | 15.34 | Sell |
| ADX (14) | 45.92 | Buy |
| ATR (14) | 0.41 | Info |
The 30-day technical picture is bullish with RSI14 at 70. The 50-day simple moving average is $10.59 and the 200-day simple moving average is $6.73. Support is seen at $8.22 and resistance at $15.88.
The 30-day range runs from $11.53 to $18.31, indicating likely near-term volatility within that band. The annualized volatility stands at 70, signaling notable movement potential in the near term.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $4.33 | $14.53 | $20.67 | 0% | Neutral | |
| $13.46 | $17.45 | $24.18 | +20% | Bullish | |
| $14.34 | $19.27 | $27.91 | +33% | Bullish | |
| $15.55 | $21.54 | $32.29 | +48% | Bullish | |
| $18.42 | $26.22 | $40.46 | +80% | Bullish | |
| $22.20 | $32.40 | $51.28 | +123% | Bullish | |
| $26.31 | $39.31 | $63.64 | +171% | Bullish | |
| $28.40 | $43.39 | $71.71 | +199% | Bullish | |
| $27.00 | $42.13 | $70.95 | +190% | Bullish | |
| $28.89 | $46.02 | $78.87 | +217% | Bullish | |
| $43.62 | $76.35 | $140.71 | +425% | Bullish | |
| $92.12 | $191.03 | $390.91 | +12.1x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $4.33 | $14.53 | $17.11 | +0.00% |
| June 2026 | $12.01 | $14.19 | $17.23 | -2.34% |
| July 2026 | $11.93 | $14.25 | $17.60 | +0.39% |
| August 2026 | $12.47 | $15.03 | $18.80 | +5.47% |
| September 2026 | $12.58 | $15.26 | $19.31 | +1.59% |
| October 2026 | $12.30 | $15.02 | $19.18 | -1.61% |
| November 2026 | $12.54 | $15.41 | $19.84 | +2.60% |
| December 2026 | $12.90 | $15.93 | $20.67 | +3.38% |
Click any year to see its month-by-month RLYB forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, RLYB is projected to trade between $4.33 and $20.67, averaging $14.53 — a potential gain of 0% from today's $14.53. Price action looks broadly range-bound.
Rallybio Corporation's 2027 outlook centres on $17.45, within a $13.46 to $24.18 range. That is up +20% on the projected 2026 average. That marks a +20% change versus current levels. Buyers look set to stay in control over this stretch.
By 2028, RLYB could reach as high as $27.91, with a base case around $19.27 and support toward $14.34 — roughly +33% from $14.53. Momentum favours further upside here.
Expect RLYB to range from $15.55 to $32.29 through 2029. The $21.54 average target implies a +48% move from current prices. That is up +12% on the projected 2028 average. Buyers look set to stay in control over this stretch.
The RLYB price prediction for 2030 points to an average of $26.22 (low $18.42, high $40.46) — a potential gain of +80% on today's $14.53. Momentum favours further upside here.
In 2031, RLYB is projected to trade between $22.20 and $51.28, averaging $32.40 — a potential gain of +123% from today's $14.53. That is up +24% on the projected 2030 average. Buyers look set to stay in control over this stretch.
Rallybio Corporation's 2032 outlook centres on $39.31, within a $26.31 to $63.64 range. That is up +21% on the projected 2031 average. That marks a +171% change versus current levels. Momentum favours further upside here.
By 2033, RLYB could reach as high as $71.71, with a base case around $43.39 and support toward $28.40 — roughly +199% from $14.53. Buyers look set to stay in control over this stretch.
Expect RLYB to range from $27.00 to $70.95 through 2034. The $42.13 average target implies a +190% move from current prices. That is -3% versus the projected 2033 average. Momentum favours further upside here.
The RLYB price prediction for 2035 points to an average of $46.02 (low $28.89, high $78.87) — a potential gain of +217% on today's $14.53. Buyers look set to stay in control over this stretch.
In 2040, RLYB is projected to trade between $43.62 and $140.71, averaging $76.35 — a potential gain of +425% from today's $14.53. That is up +66% on the projected 2035 average. Momentum favours further upside here.
Rallybio Corporation's 2050 outlook centres on $191.03, within a $92.12 to $390.91 range. That is up +150% on the projected 2040 average. That marks a +12.1x change versus current levels. Buyers look set to stay in control over this stretch.
Investing $1,000 in RLYB today (≈ 68.823125 RLYB) could be worth
$13,147.17
+$12,147.17 (+1215%) by 2050 · US Dollar
Based on the average projected RLYB price of $191.03 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in RLYBwould be worth at today's price.
$1,000 invested in RLYB on May 27, 2025 (≈ 390.625009 RLYB) would be worth
$5,675.78
+$4,675.78 (+467.6%) today · 5.68× · US Dollar
Based on a RLYB entry price of $2.56 vs. today's $14.53.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $14.58 | $996.57 | -0.3% |
| 1 month ago | $8.78 | $1,654.9 | +65.5% |
| 3 months ago | $6.8 | $2,136.76 | +113.7% |
| 6 months ago | $5.21 | $2,789.94 | +179.0% |
| 1 year ago | $2.56 | $5,675.78 | +467.6% |
| All time (4.8y) ago | $112.8 | $128.81 | -87.1% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our RLYB forecast.
Our base-case forecast reaches $29.00 around 2031.
Implied market cap at $29.00: $153.65M
The multi-year forecast shows a clear upward trajectory in average price from 2026 through 2050. The 2026 avg is $14.53, rising to $26.22 by 2030, then to $76.35 by 2040 and $191.03 by 2050. Corresponding max targets reach $20.67 (2026) and $390.91 (2050), with ROIs climbing from 0% in 2026 to 80.5% in 2030 and up to 1214.7% by 2050.
Sentiment shifts from NEUTRAL in 2026 to BULLISH from 2027 onward, reflecting a strong longer-term upside despite early uncertainty. These figures are estimates and not guarantees, and actual results may differ due to various market and company-specific factors.
Tap a question to reveal the answer.
In 2030, the avg price is $26.22, with a min of $18.42 and a max of $40.46, and a forecast ROI of 80.5%; sentiment is BULLISH.
The forecast shows a bullish sentiment from 2027 onward with rising avg prices (e.g., $17.45 in 2027, $26.22 in 2030) and increasing ROI (up to 1214.7% by 2050), but these are estimates and not guarantees.
Yes. The 2040 max is $140.71 and the 2050 max is $390.91, indicating potential to exceed $100 in the forecast horizon.
The 30-day range is $11.53 to $18.31. RSI14 is 70, SMA50 is $10.59, SMA200 is $6.73, with support at $8.22 and resistance at $15.88.
Current price is $14.53 and market cap is $76.98M; the stock is ranked 4340 by market cap.
Rallybio Corporation Community Discussion
0Share your Rallybio Corporation price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.